Antagonism of IL-4 signaling by a phosphodiesterase-4 inhibitor, rolipram, in human T cells

被引:7
|
作者
Markova, Tzvetanka Petrova
Niwa, Atsuko
Yamanishi, Hiromichi
Aragane, Yoshinori
Higashino, Hideaki
机构
[1] Int Tougenkai Inst Phototherapy & Immunotherapy S, Dermatol Sect, Nishi Ku, Osaka 5500012, Japan
[2] Kinki Univ, Sch Med, Dept Pharmacol, Osakasayama, Japan
[3] Hirakata Ryoikuen, Hirakata, Osaka, Japan
关键词
AP-1; components; cAMP; IL-4; IL-5; PDE4; inhibitors; PKA; rolipram; signal transduction; T cells;
D O I
10.1159/000099465
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Phosphodiesterase (PDE4) inhibitors prevent breakdown of cAMP and affect the increase in cellular levels of cAMP, which is known to regulate immune cell functions. Because IL-4 plays a causal role in the pathogenesis of allergic disorders, we were interested to study the modulatory mechanisms of a PDE4 inhibitor, rolipram, in IL-4-mediated signaling in T cells. Methods: Human peripheral T cells were stimulated with IL-4 in combination with rolipram, and RTPCR was performed using primers specific for IL-5. To monitor activation of transcription factors, immunostaining was employed. Results: Rolipram or a cAMP-analogue, 8- Br-cAMP, significantly downregulated IL-4-induced expression of IL-5 mRNA. The rolipram-induced inhibition of IL-5 mRNA was mediated by activation of protein kinase A (PKA), because rolipram-downregulated mRNA expression of IL-5 was restored by PKA inhibitors. Immunostaining revealed that rolipram interfered with IL-4-induced nuclear translocation of activator protein (AP)-1 components. Conclusions: This is the first demonstration of suppression of IL-4 signaling by PDE4 inhibitors via prevention of nuclear translocation of AP-1. Copyright (c) 2007 S. Karger AG, Basel
引用
收藏
页码:216 / 224
页数:9
相关论文
共 50 条
  • [21] Attenuation of ethanol abstinence-induced anxiety- and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents
    Mei-Fang Gong
    Rui-Ting Wen
    Ying Xu
    Jian-Chun Pan
    Ning Fei
    Yan-Meng Zhou
    Jiang-Ping Xu
    Jian-Hui Liang
    Han-Ting Zhang
    Psychopharmacology, 2017, 234 : 3143 - 3151
  • [22] Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography
    DaSilva, JN
    Lourenco, CM
    Meyer, JH
    Hussey, D
    Potter, WZ
    Houle, S
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (12) : 1680 - 1683
  • [23] Investigation Into the Equine Metabolism of Phosphodiesterase-4 Inhibitor Roflumilast for Potential Doping Control
    Philip, Moses
    Kal, Abdul Khader Karakka
    Subhahar, Michael Benedict
    Karatt, Tajudheen K.
    Graiban, Fatma Mohammed
    Ajeebsanu, Meleparappil Muhammed
    Joseph, Marina
    Jose, Shantymol V.
    DRUG TESTING AND ANALYSIS, 2024,
  • [24] Analysis of (R)- and (S)-[11C]rolipram Kinetics in Canine Myocardium for the Evaluation of Phosphodiesterase-4 with PET
    Lortie, Mireille
    DaSilva, Jean N.
    Kenk, Miran
    Thorn, Stephanie
    Davis, Darryl
    Birnie, David
    Beanlands, Rob S. B.
    deKemp, Robert A.
    MOLECULAR IMAGING AND BIOLOGY, 2012, 14 (02) : 225 - 236
  • [25] PET Measurements of cAMP-Mediated Phosphodiesterase-4 with (R)-[C-11] Rolipram
    Kenk, Miran
    Thomas, Adam
    Lortie, Mireille
    deKemp, Rob
    Beanlands, Rob S.
    DaSilva, Jean N.
    CURRENT RADIOPHARMACEUTICALS, 2011, 4 (01) : 44 - 58
  • [26] Phosphodiesterase 4 inhibitor rolipram potentiates the inhibitory effect of calcitonin on osteoclastogenesis
    Miyamoto, Ken-ichi
    Nishioka, Tatsuo
    Waki, Yoshihiro
    Nomura, Masaaki
    Katsuta, Hiromu
    Yokogawa, Koichi
    Amano, Hitoshi
    JOURNAL OF BONE AND MINERAL METABOLISM, 2006, 24 (04) : 260 - 265
  • [27] Effect of phosphodiesterase type 4 inhibitor rolipram on cyclophosphamide-induced cystitis in rats
    Bueyueknacar, Hacer Sinem
    Kumcu, Eda Karabal
    Goecmen, Cemil
    Oender, Serpil
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 586 (1-3) : 293 - 299
  • [28] The Phosphodiesterase Type 4 Inhibitor, Rolipram, Enhances Glucocorticoid Receptor Function
    Andrew H Miller
    Gerald J Vogt
    Bradley D Pearce
    Neuropsychopharmacology, 2002, 27 : 939 - 948
  • [29] Phosphodiesterase 4 inhibitor rolipram potentiates the inhibitory effect of calcitonin on osteoclastogenesis
    Ken-ichi Miyamoto
    Tatsuo Nishioka
    Yoshihiro Waki
    Masaaki Nomura
    Hiromu Katsuta
    Koichi Yokogawa
    Hitoshi Amano
    Journal of Bone and Mineral Metabolism, 2006, 24 : 260 - 265
  • [30] The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function
    Miller, AH
    Vogt, GJ
    Pearce, BD
    NEUROPSYCHOPHARMACOLOGY, 2002, 27 (06) : 939 - 948